• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Basic and Clinical Andrology >A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
【24h】

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

机译：从促性腺激素释放激素拮抗剂到促性腺激素释放激素激动剂治疗的改变不会影响激素敏感性前列腺癌的肿瘤学结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of changing the treatment from degarelix to a gonadotropin releasing hormone agonist after achieving stable disease control, on the clinical and oncological outcomes. Our analysis was based on the data of 108 patients with prostate cancer who were treated with degarelix. Of these, the treatment was changed from degarelix to a gonadotropin releasing hormone agonist in 57 patients (changed group), and the treatment with degarelix was continued in the other 51 (continued group). The overall 5-year survival was statistically superior in the changed (96.6%) group than that in the continued (74.1%) group (p?=?0.006). The 5-year cancer-specific survival was also superior in the changed (100%) group than that in the continued (84.6%) group (p?=?0.027). The average time to castration resistant prostate cancer was comparable in both the changed (43.3?months) and continued (35.2?months) groups (p?=?0.117). Lower serum levels of prostate specific antigen and alkaline phosphatase were maintained after changing the therapy from degarelix to a gonadotropin releasing hormone agonist. Degarelix is effective in the treatment of prostate cancer. Degarelix therapy can also be safely changed to a gonadotropin releasing hormone agonist without any adverse clinical or oncological effects.
机译：我们的回顾性研究的目的是评估接受促性腺激素释放激素拮抗剂地加瑞克治疗的激素敏感性前列腺癌患者的5年生存率和去势抵抗性前列腺癌的时间。另一个目标是评估在达到稳定的疾病控制后，将治疗方法从地加瑞克改为释放促性腺激素释放激素激动剂，对临床和肿瘤学结果的影响。我们的分析是基于108例地加瑞克治疗的前列腺癌患者的数据。其中，有57例患者从地加瑞克改用促性腺激素释放激素激动剂（变更组），其他51例继续用地加瑞克治疗（续组）。改变组（96.6％）的总体5年生存率在统计学上优于持续组（74.1％）（p≥0.006）。改变组（100％）的5年癌症特异性生存率也比继续组（84.6％）要好（p≥0.027）。在改变组（43.3个月）和持续组（35.2个月）中，去势抵抗性前列腺癌的平均时间是可比的（p≥0.117）。将治疗方法从地加瑞克改为放性激素释放激素激动剂后，可以维持较低的血清前列腺特异性抗原和碱性磷酸酶水平。 Degarelix对前列腺癌有效。 Degarelix疗法也可以安全地更改为促性腺激素释放激素激动剂，而不会产生任何不良临床或肿瘤影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号